SG Americas Securities
FDMT icon

SG Americas Securities’s 4D Molecular Therapeutics FDMT Stock Holding History

SG Americas Securities’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$884K Buy
+66,440
New +$647K ﹤0.01% 1966
2026
Q1 		– Sell
-15,531
Closed -$116K – 3386
2025
Q4 		$116K Buy
+15,531
New +$158K ﹤0.01% 3166
2025
Q3 		– Sell
-17,193
Closed -$64K – 3436
2025
Q2 		$64K Sell
17,193
-5,681
-25% -$20K ﹤0.01% 2728
2025
Q1 		$74K Sell
22,874
-7,010
-23% -$33K ﹤0.01% 3140
2024
Q4 		$166K Buy
29,884
+174
+0.6% +$1.36K ﹤0.01% 2324
2024
Q3 		$321K Buy
+29,710
New +$493K ﹤0.01% 2083
2024
Q2 		– Sell
-4,583
Closed -$146K – 2995
2024
Q1 		$146K Sell
4,583
-22,316
-83% -$569K ﹤0.01% 2229
2023
Q4 		$545K Buy
26,899
+14,645
+120% +$193K 0.01% 1423
2023
Q3 		$156K Buy
+12,254
New +$205K ﹤0.01% 2473
2023
Q2 		– Sell
-6,275
Closed -$108K – 2564
2023
Q1 		$108K Sell
6,275
-2,356
-27% -$45.8K ﹤0.01% 2851
2022
Q4 		$192K Sell
8,631
-12,606
-59% -$195K ﹤0.01% 2225
2022
Q3 		$171K Buy
21,237
+5,928
+39% +$53.7K ﹤0.01% 2439
2022
Q2 		$107K Buy
15,309
+6,967
+84% +$67.7K ﹤0.01% 3085
2022
Q1 		$126K Sell
8,342
-1,338
-14% -$21K ﹤0.01% 2673
2021
Q4 		$212K Sell
9,680
-4,517
-32% -$111K ﹤0.01% 2642
2021
Q3 		$383K Buy
14,197
+4,932
+53% +$141K ﹤0.01% 2733
2021
Q2 		$223K Buy
+9,265
New +$284K ﹤0.01% 2288
2021
Q1 		– Sell
-33,680
Closed -$1.4M – 3362
2020
Q4 		$1.4M Buy
+33,680
New +$1.39M 0.01% 1328

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

SG Americas Securities's FDMT Position: Q2 2026 in Review

SG Americas Securities opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 66,440 shares worth $884K. The stake represents ﹤0.01% of the portfolio and ranks #1966 among its holdings. This is a return to the name: SG Americas Securities previously reported a position in FDMT as recently as Q4 2025.

SG Americas Securities first reported a position in FDMT in Q4 2020 and has held it in 18 quarters since. The position peaked at $1.4M in Q4 2020. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • SG Americas Securities held 66,440 shares of 4D Molecular Therapeutics worth $884K as of Q2 2026.
  • 4D Molecular Therapeutics was a new SG Americas Securities position in Q2 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1966 holding.
  • SG Americas Securities first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 18 quarters since.
  • SG Americas Securities's 4D Molecular Therapeutics position peaked at $1.4M in Q4 2020.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.